Getting Real or Keeping It Real?
By Business Review Editor
Pharma Deals Review: Vol 2007 Issue 89 (Table of Contents)
Published: 7 Nov-2007
DOI: 10.3833/pdr.v2007.i89.266 ISSN: 1756-7874
Section: General
Fulltext:
Abstract
The risk-adjusted or expected net present value (rNPV or eNPV) method combining decision-tree and discounted cash flow analysis is most frequently used for valuing pharma R&D projects and licensing deals...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS